Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters | Zendy

Joseph S. Cavanaugh | Zendy; Ruwen Jou | Zendy; Mei-Hua Wu | Zendy; Tracy Dalton | Zendy; Ekaterina V. Kurbatova | Zendy; Julia Ershova | Zendy; J. Peter Cegielski | Zendy

Open Access

Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters

Author(s) -

Joseph S. Cavanaugh,

Ruwen Jou,

Mei-Hua Wu,

Tracy Dalton,

Ekaterina V. Kurbatova,

Julia Ershova,

J. Peter Cegielski

Publication year - 2017

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkx022

Subject(s) - clofazimine , nitazoxanide , medicine , trimethoprim , pharmacology , linezolid , meropenem , ertapenem , microbiology and biotechnology , antibacterial agent , antibiotics , biology , vancomycin , antibiotic resistance , staphylococcus aureus , immunology , leprosy , genetics , bacteria

The second-line drugs recommended to treat drug-resistant TB are toxic, expensive and difficult to procure. Given increasing resistance, the need for additional anti-TB drugs has become more urgent. But new drugs take time to develop and are expensive. Some commercially available drugs have reported anti-mycobacterial activity but are not routinely used because supporting laboratory and clinical evidence is sparse.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research